Sector News

Abbott snaps up Glomed for undisclosed price

September 7, 2016
Life sciences

Abbott picked up Vietnamese drug manufacturer Glomed for an undisclosed price in a deal that gives the pharma giant two manufacturing facilities in that country in addition to expanding its visibility in Southeast Asia.

U.S.-based Abbott, which has a 20-year presence in Vietnam, is known in the region for its formula milk. With the Glomed transaction, Abbott picks up two manufacturing plants in Vietnam’s Binh Duong province, 5 branches and more than 800 employees.

Abbott said it intends to focus on anti-infectives, gastroenterology, pain management, cardiovascular, respiratory and women’s health, and over-the-counter products.

The company is already known in the area for nutrition and its portfolio in medical devices and diagnostics.

“The company intends to build on Glomed’s success to date to ensure long-term growth in the country,” Ngo Van Huy, general manager of Abbott Vietnam’s pharmaceuticals business, told VN Express, adding that the deal will enhance Abbott’s ability to serve patients in Vietnam with innovative, high-quality healthcare solutions.

Vietnam has been opening its doors to more foreign investment over a number of industries in the wake of new policies such as the signing of the Trans-Pacific Partnership trade pact.

In July, Tokyo-based Taisho Pharmaceutical bought a 24.5% stake in Vietnam’s DHG Pharmaceutical, the country’s top drug distributor that handles a wide variety of prescription therapies, over-the-counter treatments and personal care products.

By Joseph Keenan

Source: Fierce Pharma

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach